Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Catheter Precision, Inc. on February 4, 2025, reporting events that occurred on January 29, 2025. The Company is incorporated in Delaware and trades on the NYSE American under the symbol VTAK. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation grants rather than financial performance results.
Material Changes and Executive Compensation
On January 29, 2025, the Compensation Committee awarded incentive stock options to two executive officers under the 2023 Executive Incentive Plan. The exercise price for all grants is $0.42 per share with a ten-year term.
- David Jenkins (Chairman and CEO): Granted options to purchase 450,000 shares.
- 90,000 shares vested immediately on January 29, 2025.
- 120,000 shares vest annually on January 29, 2026, 2027, and 2028.
- Marie-Claude Jacques (Chief Commercial Officer): Granted options to purchase 250,000 shares.
- Time-Based Vesting (125,000 shares): 20% vests annually from January 29, 2025, through January 29, 2029.
- Performance-Based Vesting (125,000 shares): 25% vests quarterly (March 31, June 30, September 30, and December 31, 2025) contingent upon achieving specific sales targets for Q1, Q2, Q3, and Q4 2025.
Guidance, Outlook, and Risks
The filing does not contain general business guidance, outlook, or risk factors. However, the performance-based vesting schedule for the Chief Commercial Officer implies specific, undisclosed sales targets for each quarter of 2025. Failure to meet these targets will result in the forfeiture of the associated option grants.
Key Facts for Investor Verification
- Verify the specific sales targets required for the performance-based vesting of Marie-Claude Jacques' options, as these are not detailed in this filing.
- Confirm the total number of shares available under the 2023 Executive Incentive Plan to assess dilution impact.
- Review the Company's most recent 10-K or 10-Q for current revenue trends to gauge the feasibility of the 2025 sales targets.
- Monitor future filings for any changes to the vesting schedule or exercise price.